Varenicline has been approved in the USA for the treatment of dry eye disease via the activation of tear film production. In this touchOPHTHALMOLOGY interview, Dr Cynthia Matossian (Matossian Eye Associates, New Hope, PA, USA) discusses the aims and design of her randomized, controlled, double-blinded study which evaluates tear film quality and stability in patients using varenicline solution nasal spray as compared to vehicle control nasal spray. Dr Cynthia Matossian also discusses the findings of the study as well as the implications.
The abstract entitled ‘Varenicline and Tear Film Imaging: Preliminary Study Results’ was presented at Hawaiian Eye and Retina meeting, 14-20 January 2023.
Questions:
- Could you tell us a little a little about varenicline and its uses? (0:25)
- What were the aims and design of your study? (1:28)
- What have been the preliminary findings of your study, and what are their implications? (3:49)
Disclosures: Cynthia Matossian is a consultant for Oyster Point Pharma.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Lisa Glass.
Filmed as a highlight of Hawaiin Eye
Access more content on Cataract Surgery here
